AMAG Pharmaceuticals reviews Feraheme net product revenues of $13.

AMAG received a $60 million upfront payment and can be eligible to receive up to $220 million in development and commercial milestones. Additionally, AMAG shall receive tiered, double-digit royalties based on net sales of Feraheme in the licensed territories. Through the first one fourth, AMAG initiated enrollment in a medical trial, the ferumoxytol compared to iron sucrose trial , in 150 sufferers with chronic kidney disease and iron deficiency anemia to support the European regulatory submitting for Feraheme. Feraheme Release Highlights AMAG reported first one fourth 2010 Feraheme net product revenues of $13.1 million, including $2.2 million of deferred product revenues previously.In addition, although the inclusion of periprocedural myocardial infarction as a finish point is useful to increase the number of events in scientific trials, its clinical relevance continues to be debated.18-21 Our results do not show an impact of cangrelor on periprocedural myocardial infarction except in the subgroup of individuals with a negative troponin test at baseline but do present an impact of cangrelor on even more essential outcomes than in the CHAMPION PCI trial . Therefore, if one contrasts the total results of both CHAMPION trials, it appears that the 600 mg loading dose of clopidogrel might provide incremental benefit when given in the beginning of the procedure versus only by the end, though this summary remains speculative.